10 Best Multibagger Penny Stocks to Buy According to Billionaires

7. Personalis, Inc. (NASDAQ:PSNL)

Number of Billionaire Holders: 5

1-Year Gain as of April 21: 153.17%

Share Price as of April 21: $3.19

Personalis, Inc. (NASDAQ:PSNL) is a diagnostic and research company that develops markets and sells advanced cancer genomic tests and services. It offers NeXT Personal, a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumour cancers. While the stock is up by 153.17% over the past year, Craig Hallum initiated coverage of the stock with a Buy recommendation on March 17.

The impressive run stems from a solid 2024 that saw Personalis, Inc. (NASDAQ:PSNL) presenting compelling clinical data at medical conferences, as it also drove testing growth by 52%. In addition, Personalis strengthened its long-term prospects with a $50 million strategic investment from Merck and inked a commercial collaboration with Moderna.

The partnership with Moderna for V940/mRNA-4157 places Personalis, Inc. (NASDAQ:PSNL) in a leading role in the advancement of personalized neoantigen therapy. The ongoing choice of their ImmunoID NeXT Platform highlights its technical excellence in tumor profiling and neoantigen discovery. The platform’s capability to facilitate the development of tailored cancer vaccines provides a significant competitive edge in the swiftly changing precision oncology arena.